vs
景顺（IVZ）与福泰制药（VRTX）财务数据对比。点击上方公司名可切换其他公司
福泰制药的季度营收约是景顺的1.9倍（$3.2B vs $1.7B），福泰制药净利率更高（37.3% vs -58.9%，领先96.2%），福泰制药同比增速更快（9.5% vs 6.2%），景顺自由现金流更多（$432.2M vs $348.6M），过去两年福泰制药的营收复合增速更高（8.9% vs 7.1%）
景顺是总部位于美国佐治亚州亚特兰大的独立投资管理企业，在全球20个国家设有分支机构，旗下运营景顺、Invesco Perpetual、PowerShares等品牌，普通股为标普500指数成分股，于纽约证券交易所挂牌交易。
福泰制药是总部位于美国马萨诸塞州波士顿的生物制药企业，是全球首批明确采用理性药物设计策略、而非组合化学方法开发药物的生物技术公司之一。除波士顿总部外，公司还在加州圣迭戈、英国牛津郡米尔顿公园设有三处研发中心。
IVZ vs VRTX — 直观对比
营收规模更大
VRTX
是对方的1.9倍
$1.7B
营收增速更快
VRTX
高出3.3%
6.2%
净利率更高
VRTX
高出96.2%
-58.9%
自由现金流更多
IVZ
多$83.6M
$348.6M
两年增速更快
VRTX
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $3.2B |
| 净利润 | $-995.9M | $1.2B |
| 毛利率 | — | 85.4% |
| 营业利润率 | -86.2% | 37.8% |
| 净利率 | -58.9% | 37.3% |
| 营收同比 | 6.2% | 9.5% |
| 净利润同比 | -575.8% | 30.5% |
| 每股收益（稀释后） | $-2.61 | $4.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IVZVRTX
| Q4 25 | $1.7B | $3.2B | ||
| Q3 25 | $1.6B | $3.1B | ||
| Q2 25 | $1.5B | $3.0B | ||
| Q1 25 | $1.5B | $2.8B | ||
| Q4 24 | $1.6B | $2.9B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.5B | $2.6B | ||
| Q1 24 | $1.5B | $2.7B |
净利润IVZVRTX
| Q4 25 | $-995.9M | $1.2B | ||
| Q3 25 | $356.4M | $1.1B | ||
| Q2 25 | $197.4M | $1.0B | ||
| Q1 25 | $171.1M | $646.3M | ||
| Q4 24 | $209.3M | $913.0M | ||
| Q3 24 | $55.0M | $1.0B | ||
| Q2 24 | $132.2M | $-3.6B | ||
| Q1 24 | $141.5M | $1.1B |
毛利率IVZVRTX
| Q4 25 | — | 85.4% | ||
| Q3 25 | — | 86.5% | ||
| Q2 25 | — | 86.3% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 85.5% | ||
| Q3 24 | — | 85.8% | ||
| Q2 24 | — | 85.9% | ||
| Q1 24 | — | 87.3% |
营业利润率IVZVRTX
| Q4 25 | -86.2% | 37.8% | ||
| Q3 25 | 16.5% | 38.6% | ||
| Q2 25 | 14.1% | 38.8% | ||
| Q1 25 | 18.1% | 22.7% | ||
| Q4 24 | 19.6% | 35.2% | ||
| Q3 24 | 6.6% | 40.3% | ||
| Q2 24 | 13.9% | -132.9% | ||
| Q1 24 | 14.4% | 42.4% |
净利率IVZVRTX
| Q4 25 | -58.9% | 37.3% | ||
| Q3 25 | 21.7% | 35.2% | ||
| Q2 25 | 13.0% | 34.8% | ||
| Q1 25 | 11.2% | 23.3% | ||
| Q4 24 | 13.1% | 31.4% | ||
| Q3 24 | 3.6% | 37.7% | ||
| Q2 24 | 8.9% | -135.8% | ||
| Q1 24 | 9.6% | 40.9% |
每股收益（稀释后）IVZVRTX
| Q4 25 | $-2.61 | $4.64 | ||
| Q3 25 | $0.66 | $4.20 | ||
| Q2 25 | $-0.03 | $3.99 | ||
| Q1 25 | $0.38 | $2.49 | ||
| Q4 24 | $0.46 | $3.62 | ||
| Q3 24 | $0.12 | $4.01 | ||
| Q2 24 | $0.29 | $-13.92 | ||
| Q1 24 | $0.31 | $4.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0B | $6.6B |
| 总债务越低越好 | $1.8B | — |
| 股东权益账面价值 | $12.2B | $18.7B |
| 总资产 | $27.1B | $25.6B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资IVZVRTX
| Q4 25 | $1.0B | $6.6B | ||
| Q3 25 | $973.1M | $6.3B | ||
| Q2 25 | $922.7M | $6.4B | ||
| Q1 25 | $821.7M | $6.2B | ||
| Q4 24 | $986.5M | $6.1B | ||
| Q3 24 | $1.0B | $6.5B | ||
| Q2 24 | $878.5M | $5.8B | ||
| Q1 24 | $895.7M | $10.2B |
总债务IVZVRTX
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $964.8M | — | ||
| Q4 24 | $890.6M | — | ||
| Q3 24 | $890.3M | — | ||
| Q2 24 | $890.1M | — | ||
| Q1 24 | $1.3B | — |
股东权益IVZVRTX
| Q4 25 | $12.2B | $18.7B | ||
| Q3 25 | $14.0B | $17.3B | ||
| Q2 25 | $13.9B | $17.2B | ||
| Q1 25 | $14.7B | $16.5B | ||
| Q4 24 | $14.6B | $16.4B | ||
| Q3 24 | $14.8B | $15.6B | ||
| Q2 24 | $14.6B | $14.8B | ||
| Q1 24 | $14.6B | $18.5B |
总资产IVZVRTX
| Q4 25 | $27.1B | $25.6B | ||
| Q3 25 | $28.4B | $24.9B | ||
| Q2 25 | $28.5B | $24.0B | ||
| Q1 25 | $28.1B | $22.9B | ||
| Q4 24 | $27.0B | $22.5B | ||
| Q3 24 | $27.5B | $22.2B | ||
| Q2 24 | $27.2B | $20.1B | ||
| Q1 24 | $28.1B | $23.9B |
负债/权益比IVZVRTX
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.06× | — | ||
| Q1 24 | 0.09× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $455.8M | $498.0M |
| 自由现金流经营现金流 - 资本支出 | $432.2M | $348.6M |
| 自由现金流率自由现金流/营收 | 25.5% | 10.9% |
| 资本支出强度资本支出/营收 | 1.4% | 4.7% |
| 现金转化率经营现金流/净利润 | — | 0.42× |
| 过去12个月自由现金流最近4个季度 | $1.4B | $3.2B |
8季度趋势，按日历期对齐
经营现金流IVZVRTX
| Q4 25 | $455.8M | $498.0M | ||
| Q3 25 | $606.2M | $1.2B | ||
| Q2 25 | $547.9M | $1.1B | ||
| Q1 25 | $-84.6M | $818.9M | ||
| Q4 24 | $316.9M | $584.6M | ||
| Q3 24 | $438.4M | $1.4B | ||
| Q2 24 | $489.1M | $-3.8B | ||
| Q1 24 | $-54.4M | $1.3B |
自由现金流IVZVRTX
| Q4 25 | $432.2M | $348.6M | ||
| Q3 25 | $586.4M | $1.1B | ||
| Q2 25 | $530.4M | $927.4M | ||
| Q1 25 | $-108.0M | $778.2M | ||
| Q4 24 | $309.9M | $492.0M | ||
| Q3 24 | $410.0M | $1.3B | ||
| Q2 24 | $462.4M | $-3.8B | ||
| Q1 24 | $-75.4M | $1.2B |
自由现金流率IVZVRTX
| Q4 25 | 25.5% | 10.9% | ||
| Q3 25 | 35.7% | 37.0% | ||
| Q2 25 | 35.0% | 31.3% | ||
| Q1 25 | -7.1% | 28.1% | ||
| Q4 24 | 19.5% | 16.9% | ||
| Q3 24 | 27.1% | 47.0% | ||
| Q2 24 | 31.2% | -144.5% | ||
| Q1 24 | -5.1% | 46.0% |
资本支出强度IVZVRTX
| Q4 25 | 1.4% | 4.7% | ||
| Q3 25 | 1.2% | 3.3% | ||
| Q2 25 | 1.2% | 4.9% | ||
| Q1 25 | 1.5% | 1.5% | ||
| Q4 24 | 0.4% | 3.2% | ||
| Q3 24 | 1.9% | 2.4% | ||
| Q2 24 | 1.8% | 2.6% | ||
| Q1 24 | 1.4% | 2.5% |
现金转化率IVZVRTX
| Q4 25 | — | 0.42× | ||
| Q3 25 | 1.70× | 1.15× | ||
| Q2 25 | 2.78× | 1.04× | ||
| Q1 25 | -0.49× | 1.27× | ||
| Q4 24 | 1.51× | 0.64× | ||
| Q3 24 | 7.97× | 1.31× | ||
| Q2 24 | 3.70× | — | ||
| Q1 24 | -0.38× | 1.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IVZ
| Investment Advice | $1.2B | 73% |
| Distribution And Shareholder Service | $382.7M | 23% |
| Financial Service Other | $51.0M | 3% |
| Investment Performance | $28.9M | 2% |
VRTX
| TRIKAFTAKAFTRIO | $2.6B | 81% |
| ALYFTREK | $380.1M | 12% |
| Manufactured Product Other | $237.4M | 7% |
